AAPL325.84+0.71 (+0.22%) ▲|ABBV259.84-0.15 (-0.06%) ▼|ABT111.32+2.39 (+2.19%) ▲|ACN187.12-0.97 (-0.52%) ▼|ADBE281.61-4.47 (-1.56%) ▼|AMAT438.54-3.31 (-0.75%) ▼|AMD456.87-2.74 (-0.60%) ▼|AMGN438.17+0.05 (+0.01%) ▲|AMT172.15-3.87 (-2.20%) ▼|AMZN254.77-0.15 (-0.06%) ▼|AVGO368.52-1.17 (-0.32%) ▼|AXP329.30+5.11 (+1.58%) ▲|BA209.56+3.90 (+1.90%) ▲|BAC62.38+0.39 (+0.62%) ▲|BKNG199.29+3.60 (+1.84%) ▲|BLK1,109.93-18.18 (-1.61%) ▼|BMY67.25+0.33 (+0.49%) ▲|BNY161.23+0.72 (+0.45%) ▲|BRK-B507.84+5.51 (+1.10%) ▲|C133.51+0.97 (+0.73%) ▲|CAT784.15+4.99 (+0.64%) ▲|CL90.72+1.09 (+1.22%) ▲|CMCSA27.13+0.83 (+3.14%) ▲|COF216.74+5.40 (+2.55%) ▲|COP136.78+0.59 (+0.43%) ▲|COST930.24-9.73 (-1.03%) ▼|CRM254.45-3.66 (-1.42%) ▼|CSCO108.89-0.86 (-0.78%) ▼|CVS98.11+0.51 (+0.52%) ▲|CVX211.96+0.91 (+0.43%) ▲|DE684.61+8.53 (+1.26%) ▲|DHR209.43+2.50 (+1.21%) ▲|DIS108.66+2.44 (+2.30%) ▲|DUK120.61+0.22 (+0.18%) ▲|EMR148.52+0.89 (+0.60%) ▲|FDX321.59-3.29 (-1.01%) ▼|GD364.09-5.33 (-1.44%) ▼|GE330.34-0.75 (-0.23%) ▼|GEV916.36+17.83 (+1.98%) ▲|GILD149.43-0.50 (-0.33%) ▼|GM84.73-0.91 (-1.06%) ▼|GOOG334.51+2.48 (+0.75%) ▲|GOOGL338.17+3.15 (+0.94%) ▲|GS999.83-2.73 (-0.27%) ▼|HD319.65-0.12 (-0.04%) ▼|HON206.60-3.38 (-1.61%) ▼|IBM232.47+1.07 (+0.46%) ▲|INTC90.12+1.15 (+1.29%) ▲|INTU342.80-2.13 (-0.62%) ▼|ISRG373.18+3.93 (+1.07%) ▲|JNJ274.76+3.57 (+1.32%) ▲|JPM354.69-0.26 (-0.07%) ▼|KO88.67+0.67 (+0.76%) ▲|LIN488.49+1.73 (+0.36%) ▲|LLY1,159.72-0.28 (-0.02%) ▼|LMT531.67-12.84 (-2.36%) ▼|LOW201.42+1.37 (+0.68%) ▲|LRCX287.81-2.39 (-0.82%) ▼|MA588.52+7.42 (+1.28%) ▲|MCD261.19+0.08 (+0.03%) ▲|MDLZ62.62+1.01 (+1.63%) ▲|MDT93.35+1.31 (+1.42%) ▲|META593.20+14.66 (+2.53%) ▲|MMM169.72-0.52 (-0.31%) ▼|MO69.77+0.20 (+0.29%) ▲|MRK150.66+0.80 (+0.53%) ▲|MS211.03-0.02 (-0.01%) ▼|MSFT496.11-4.91 (-0.98%) ▼|MU945.58+12.14 (+1.30%) ▲|NEE82.80-0.13 (-0.16%) ▼|NFLX82.17+1.36 (+1.68%) ▲|NKE38.39+0.27 (+0.71%) ▲|NOW137.32-5.58 (-3.90%) ▼|NVDA224.96+7.52 (+3.46%) ▲|ORCL144.73+3.41 (+2.41%) ▲|PEP141.13+1.34 (+0.96%) ▲|PFE28.87+0.32 (+1.12%) ▲|PG147.91+1.70 (+1.16%) ▲|PLTR168.02-11.90 (-6.61%) ▼|PM188.50+1.35 (+0.72%) ▲|QCOM169.10+2.49 (+1.49%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO604.75+4.25 (+0.71%) ▲|TMUS187.17+5.01 (+2.75%) ▲|TSLA353.08-3.02 (-0.85%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|AAPL325.84+0.71 (+0.22%) ▲|ABBV259.84-0.15 (-0.06%) ▼|ABT111.32+2.39 (+2.19%) ▲|ACN187.12-0.97 (-0.52%) ▼|ADBE281.61-4.47 (-1.56%) ▼|AMAT438.54-3.31 (-0.75%) ▼|AMD456.87-2.74 (-0.60%) ▼|AMGN438.17+0.05 (+0.01%) ▲|AMT172.15-3.87 (-2.20%) ▼|AMZN254.77-0.15 (-0.06%) ▼|AVGO368.52-1.17 (-0.32%) ▼|AXP329.30+5.11 (+1.58%) ▲|BA209.56+3.90 (+1.90%) ▲|BAC62.38+0.39 (+0.62%) ▲|BKNG199.29+3.60 (+1.84%) ▲|BLK1,109.93-18.18 (-1.61%) ▼|BMY67.25+0.33 (+0.49%) ▲|BNY161.23+0.72 (+0.45%) ▲|BRK-B507.84+5.51 (+1.10%) ▲|C133.51+0.97 (+0.73%) ▲|CAT784.15+4.99 (+0.64%) ▲|CL90.72+1.09 (+1.22%) ▲|CMCSA27.13+0.83 (+3.14%) ▲|COF216.74+5.40 (+2.55%) ▲|COP136.78+0.59 (+0.43%) ▲|COST930.24-9.73 (-1.03%) ▼|CRM254.45-3.66 (-1.42%) ▼|CSCO108.89-0.86 (-0.78%) ▼|CVS98.11+0.51 (+0.52%) ▲|CVX211.96+0.91 (+0.43%) ▲|DE684.61+8.53 (+1.26%) ▲|DHR209.43+2.50 (+1.21%) ▲|DIS108.66+2.44 (+2.30%) ▲|DUK120.61+0.22 (+0.18%) ▲|EMR148.52+0.89 (+0.60%) ▲|FDX321.59-3.29 (-1.01%) ▼|GD364.09-5.33 (-1.44%) ▼|GE330.34-0.75 (-0.23%) ▼|GEV916.36+17.83 (+1.98%) ▲|GILD149.43-0.50 (-0.33%) ▼|GM84.73-0.91 (-1.06%) ▼|GOOG334.51+2.48 (+0.75%) ▲|GOOGL338.17+3.15 (+0.94%) ▲|GS999.83-2.73 (-0.27%) ▼|HD319.65-0.12 (-0.04%) ▼|HON206.60-3.38 (-1.61%) ▼|IBM232.47+1.07 (+0.46%) ▲|INTC90.12+1.15 (+1.29%) ▲|INTU342.80-2.13 (-0.62%) ▼|ISRG373.18+3.93 (+1.07%) ▲|JNJ274.76+3.57 (+1.32%) ▲|JPM354.69-0.26 (-0.07%) ▼|KO88.67+0.67 (+0.76%) ▲|LIN488.49+1.73 (+0.36%) ▲|LLY1,159.72-0.28 (-0.02%) ▼|LMT531.67-12.84 (-2.36%) ▼|LOW201.42+1.37 (+0.68%) ▲|LRCX287.81-2.39 (-0.82%) ▼|MA588.52+7.42 (+1.28%) ▲|MCD261.19+0.08 (+0.03%) ▲|MDLZ62.62+1.01 (+1.63%) ▲|MDT93.35+1.31 (+1.42%) ▲|META593.20+14.66 (+2.53%) ▲|MMM169.72-0.52 (-0.31%) ▼|MO69.77+0.20 (+0.29%) ▲|MRK150.66+0.80 (+0.53%) ▲|MS211.03-0.02 (-0.01%) ▼|MSFT496.11-4.91 (-0.98%) ▼|MU945.58+12.14 (+1.30%) ▲|NEE82.80-0.13 (-0.16%) ▼|NFLX82.17+1.36 (+1.68%) ▲|NKE38.39+0.27 (+0.71%) ▲|NOW137.32-5.58 (-3.90%) ▼|NVDA224.96+7.52 (+3.46%) ▲|ORCL144.73+3.41 (+2.41%) ▲|PEP141.13+1.34 (+0.96%) ▲|PFE28.87+0.32 (+1.12%) ▲|PG147.91+1.70 (+1.16%) ▲|PLTR168.02-11.90 (-6.61%) ▼|PM188.50+1.35 (+0.72%) ▲|QCOM169.10+2.49 (+1.49%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO604.75+4.25 (+0.71%) ▲|TMUS187.17+5.01 (+2.75%) ▲|TSLA353.08-3.02 (-0.85%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|
21.3 C
New York
Wednesday, September 2, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy,...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in...

CLL Society Awards Research Projects Advancing CLL/SLL Care

2025 Research Program supports innovative studies aimed at improving outcomes and quality of life for CLL and SLL patients SAN DIEGO, July 21, 2025 /PRNewswire/...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

ORION CORPORATION
PRESS RELEASE
21 JULY 2025 at 10:30 EEST          

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

Workout Routine For Men Revealed: How To Build Muscle Fast With CrazyBulk Muscle Gaining Supplements

Discover the ultimate workout routine for men and learn how to build muscle fast with expert training tips, CrazyBulk stacks, and muscle gaining supplements. Get actionable strategies and science-backed advice for rapid results, maximum strength, and a lean, powerful physique. 
Discover the ultimate workout routine for men and learn how to build muscle fast with expert training tips, CrazyBulk stacks, and muscle gaining supplements. Get actionable strategies and science-backed advice for rapid results, maximum strength, and a lean, powerful physique.

Muscle Building Supplements: How CrazyBulk Muscle Building Pills Reshape Strength Training Programs and Fast Muscle Mass Gains

Discover how CrazyBulk’s muscle building pills are redefining strength training programs and helping athletes gain muscle mass faster in 2025. 
Discover how CrazyBulk’s muscle building pills are redefining strength training programs and helping athletes gain muscle mass faster in 2025.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options

Smile Train Launches World Cleft Awareness Day to Unite Global Cleft Community

Today, Sunday, July 20, 2025, Marks the Inaugural Observance NEW YORK, July 20, 2025 /PRNewswire/ -- Smile Train, the world's largest cleft-focused organization, announces the...

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers